DPY30 promotes colorectal carcinoma metastasis by upregulating ZEB1 transcriptional expression.

"Declarations Ethics approval and consent to participateThis study was approved by the Ethics Committees of The First Affiliated Hospital of Xiamen University (Xiamen, China) (The IRB approval number: XMYY-2022KYSB097). Prior to tumor specimen collection, all patients underwent curative resection and provided written informed consent at the Department of Colorectal Tumor Surgery, First Affiliated Hospital of Xiamen University. The animal experiments were approved by and performed in accordance with the Institutional Animal Care and Use Ethics Committee of Xiamen University. Every effort was made to minimize animal suffering, and experiments were conducted according to the institution's guidelines. All methods were reported in accordance with ARRIVE guidelines (https://arriveguidelines.org) for the reporting of animal experiments. Consent for publicationAll authors have provided their consent for publication. Competing interestsThe authors declare there are no competing interests. Competing interests The authors declare there are no competing interests."

"Funding This work was supported by project grants from the National Natural Science Foundation of China (Grant Nos. 81870435 and 81970462) and the Key Medical and Health Project, Xiamen, China (Grant No. 3502Z20204001). The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript."